IP Verse

Pharmaceutical Product With Increased Stability Comprising Immunoglobulins - EP3226895

The patent EP3226895 was granted to CSL Behring on Jul 22, 2020. The application was originally filed on Dec 3, 2015 under application number EP15805446A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3226895

CSL BEHRING
Application Number
EP15805446A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Jun 19, 2020
Grant Date
Jul 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

OCTAPHARMAApr 22, 2021ULLRICH & NAUMANN PARTG MBB -

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONEP2361636
EXAMINATIONEP3202389
INTERNATIONAL-SEARCH-REPORTEP2361636
INTERNATIONAL-SEARCH-REPORTFR2995213
INTERNATIONAL-SEARCH-REPORTGB2471726
INTERNATIONAL-SEARCH-REPORTWO03039632
INTERNATIONAL-SEARCH-REPORTWO2012151247
INTERNATIONAL-SEARCH-REPORTWO2014140095
INTERNATIONAL-SEARCH-REPORTWO2014140097
OPPOSITIONFR2995213
OPPOSITIONUS2005276823
OPPOSITIONUS2008072992
OPPOSITIONUS2015224264
OPPOSITIONWO03039632
OPPOSITIONWO2007100396
OPPOSITIONWO2011104315
OPPOSITIONWO2014140097

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "SCHOTT TopPac® Polymer Prefillable Syringes", Schott AG, (20070329), pages 1 - 24, XP055952544-
OPPOSITION- "APPLICATION FOR INCLUSION OF Polyvalent Human Immunoglobulins 20% for subcutaneous administration ", CSL Behring AG, (20121101), CSL Behring AG, (20220915), XP055961227-
OPPOSITION- "AUSTRIA.CODEX FACHINFORMATION 1997/1998", (19970101), (20220915), XP055961216-
OPPOSITION- E. T. Maggio, "Use of excipients to control aggregation in peptide and protein formulations", J. Excipients and Food Chem ., (20100101), vol. 1, no. 2, pages 40 - 49, XP055560599-
OPPOSITION- "GAMMANORM Fachinformationen", Octapharma GmbH, Langenfeld, Germany, Langenfeld, Germany, (20050401), Octapharma GmbH, URL: www.octapharma.de, (20220915), XP055961213-
OPPOSITION- "Human normal immunoglobulin for intravenous administration", European Pharmacopoeia, (19970101), European Pharmacopoeia, (20220915), XP055961218-
OPPOSITION- Li Shihong, Schoneich Christian, Borchardt Ronald T, "Chemical Instability of Protein P harm aceu t ica Is : Mechanisms of Oxidation and Strategies for Stabilization", (19950101), vol. 48, XP055961210-
OPPOSITION- "Pre-Filled Syringes Forum 2008", PharmaED's, (20080101), PharmaED's, (20220915), XP055961232-
OPPOSITION- SCHOTT, TopPac® Website, XP055961209-
OPPOSITION- WANG W; SINGH S; ZENG D L; KING K; NEMA S, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", Journal of pharmaceutical sciences, (20070101), vol. 96, no. 1, doi:10.1002/jps.20727, ISSN 0022-3549, pages 1 - 26, XP009084505
OPPOSITION- Yoshino Keisuke, Nakamura Koji, Yamashita Arisa, Abe Yoshihiko, Iwasaki Kazuhiro, Kanazawa Yukie, Funatsu Kaori, Yoshimoto Tsuyoshi, Suzuki Shigeru, "Functional Evaluation and Characterization of a Newly Developed Silicone Oil-Free Prefillable Syringe System", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20140501), vol. 103, no. 5, doi:10.1002/jps.23945, ISSN 0022-3549, pages 1520 - 1528, XP055961235
OPPOSITION- Mark Cornell Manning ; Danny K. Chou ; Brian M. Murphy ; Robert W. Payne ; Derrick S. Katayama, "Stability of Protein Pharmaceuticals: An Update", Pharmaceutical Research, NL, (20100209), vol. 27, no. 4, doi:10.1007/s11095-009-0045-6, ISSN 1573-904X, pages 544 - 575, XP019793935
OPPOSITION- Torosantucci Riccardo, Schöneich Christian, Jiskoot Wim, "Oxidation of Therapeutic Proteins and Peptides: Structural and Biological Consequences", Pharmaceutical Research, DE, (20140301), vol. 31, no. 3, doi:10.1007/s11095-013-1199-9, ISSN 0724-8741, pages 541 - 553, XP093122784
OPPOSITION- Bolli, R. ; Woodtli, K. ; Bartschi, M. ; Hofferer, L. ; Lerch, P., "l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions", Biologicals, ACADEMIC PRESS LTD., LONDON., GB, GB , (20100101), vol. 38, no. 1, ISSN 1045-1056, pages 150 - 157, XP026978067

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents